List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7544639/publications.pdf Version: 2024-02-01



RENHIDLEE

#	Article	IF	CITATIONS
1	Long-term analysis of antibodies elicited by SPUTNIK V: A prospective cohort study in Tucumán, Argentina. The Lancet Regional Health Americas, 2022, 6, 100123.	2.6	21
2	Quantifying Neutralizing Antibodies in Patients with COVID-19 by a Two-Variable Generalized Additive Model. MSphere, 2022, 7, e0088321.	2.9	10
3	Single-virus assay reveals membrane determinants and mechanistic features of Sendai virus binding. Biophysical Journal, 2022, 121, 956-965.	0.5	6
4	Suppressing fatty acid synthase by type I interferon and chemical inhibitors as a broad spectrum anti-viral strategy against SARS-CoV-2. Acta Pharmaceutica Sinica B, 2022, 12, 1624-1635.	12.0	12
5	The RNA helicase DHX16 recognizes specific viral RNA to trigger RIG-I-dependent innate antiviral immunity. Cell Reports, 2022, 38, 110434.	6.4	16
6	The Impact of Evolving SARS-CoV-2 Mutations and Variants on COVID-19 Vaccines. MBio, 2022, 13, e0297921.	4.1	117
7	The IgA in milk induced by SARS-CoV-2 infection is comprised of mainly secretory antibody that is neutralizing and highly durable over time. PLoS ONE, 2022, 17, e0249723.	2.5	17
8	Classification of new morbillivirus and jeilongvirus sequences from bats sampled in Brazil and Malaysia. Archives of Virology, 2022, 167, 1977-1987.	2.1	11
9	Genome-wide CRISPR Screens Reveal Host Factors Critical for SARS-CoV-2 Infection. Cell, 2021, 184, 76-91.e13.	28.9	418
10	Loss of furin cleavage site attenuates SARS-CoV-2 pathogenesis. Nature, 2021, 591, 293-299.	27.8	579
11	Emergency response for evaluating SARS-CoV-2 immune status, seroprevalence and convalescent plasma in Argentina. PLoS Pathogens, 2021, 17, e1009161.	4.7	62
12	Quantifying Absolute Neutralization Titers against SARS-CoV-2 by a Standardized Virus Neutralization Assay Allows for Cross-Cohort Comparisons of COVID-19 Sera. MBio, 2021, 12, .	4.1	64
13	Reduced Nucleoprotein Availability Impairs Negative-Sense RNA Virus Replication and Promotes Host Recognition. Journal of Virology, 2021, 95, .	3.4	26
14	Fitness selection of hyperfusogenic measles virus F proteins associated with neuropathogenic phenotypes. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118,	7.1	15
15	Dissecting ELANE neutropenia pathogenicity by human HSC gene editing. Cell Stem Cell, 2021, 28, 833-845.e5.	11.1	23
16	Neutralizing activity of Sputnik V vaccine sera against SARS-CoV-2 variants. Nature Communications, 2021, 12, 4598.	12.8	88
17	2021 Taxonomic update of phylum Negarnaviricota (Riboviria: Orthornavirae), including the large orders Bunyavirales and Mononegavirales. Archives of Virology, 2021, 166, 3513-3566.	2.1	62
18	Proteases and variants: context matters for SARS-CoV-2 entry assays. Current Opinion in Virology, 2021, 50, 49-58.	5.4	23

#	Article	IF	CITATIONS
19	SARS-CoV-2 proteases PLpro and 3CLpro cleave IRF3 and critical modulators of inflammatory pathways (NLRP12 and TAB1): implications for disease presentation across species. Emerging Microbes and Infections, 2021, 10, 178-195.	6.5	178
20	Role of Immunoglobulin M and A Antibodies in the Neutralization of Severe Acute Respiratory Syndrome Coronavirus 2. Journal of Infectious Diseases, 2021, 223, 957-970.	4.0	64
21	Detection of Antibody Responses Against SARS-CoV-2 in Plasma and Saliva From Vaccinated and Infected Individuals. Frontiers in Immunology, 2021, 12, 759688.	4.8	29
22	Genome-wide transposon mutagenesis of paramyxoviruses reveals constraints on genomic plasticity. PLoS Pathogens, 2020, 16, e1008877.	4.7	3
23	Orally efficacious broad-spectrum allosteric inhibitor of paramyxovirus polymerase. Nature Microbiology, 2020, 5, 1232-1246.	13.3	18
24	Nipah@20: Lessons Learned from Another Virus with Pandemic Potential. MSphere, 2020, 5, .	2.9	21
25	The Viral Polymerase Complex Mediates the Interaction of Viral Ribonucleoprotein Complexes with Recycling Endosomes during Sendai Virus Assembly. MBio, 2020, 11, .	4.1	10
26	2020 taxonomic update for phylum Negarnaviricota (Riboviria: Orthornavirae), including the large orders Bunyavirales and Mononegavirales. Archives of Virology, 2020, 165, 3023-3072.	2.1	184
27	Differential Features of Fusion Activation within the Paramyxoviridae. Viruses, 2020, 12, 161.	3.3	26
28	A key region of molecular specificity orchestrates unique ephrin-B1 utilization by Cedar virus. Life Science Alliance, 2020, 3, e201900578.	2.8	22
29	Genome-wide transposon mutagenesis of paramyxoviruses reveals constraints on genomic plasticity. , 2020, 16, e1008877.		0
30	Genome-wide transposon mutagenesis of paramyxoviruses reveals constraints on genomic plasticity. , 2020, 16, e1008877.		0
31	Genome-wide transposon mutagenesis of paramyxoviruses reveals constraints on genomic plasticity. , 2020, 16, e1008877.		0
32	Taxonomy of the order Mononegavirales: second update 2018. Archives of Virology, 2019, 164, 1233-1244.	2.1	70
33	Taxonomy of the order Mononegavirales: update 2019. Archives of Virology, 2019, 164, 1967-1980.	2.1	224
34	A structural basis for antibody-mediated neutralization of Nipah virus reveals a site of vulnerability at the fusion glycoprotein apex. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 25057-25067.	7.1	53
35	Diversity, pathogenicity and pandemic potential of Henipavirus: an interview with Benhur Lee. Future Virology, 2019, 14, 449-451.	1.8	0
36	ICTV Virus Taxonomy Profile: Paramyxoviridae. Journal of General Virology, 2019, 100, 1593-1594.	2.9	194

#	Article	IF	CITATIONS
37	Taxonomy of the order Mononegavirales: update 2018. Archives of Virology, 2018, 163, 2283-2294.	2.1	153
38	Problems of classification in the family Paramyxoviridae. Archives of Virology, 2018, 163, 1395-1404.	2.1	30
39	Evolution of Codon Usage Bias in Henipaviruses Is Governed by Natural Selection and Is Host-Specific. Viruses, 2018, 10, 604.	3.3	35
40	IL-15 regulates susceptibility of CD4 <sup>+</sup> T cells to HIV infection. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E9659-E9667.	7.1	43
41	Greasing the receptor. Nature Microbiology, 2018, 3, 1082-1083.	13.3	2
42	Protect NIH's DNA advisory committee. Science, 2018, 362, 409-410.	12.6	2
43	Favipiravir (T-705) protects against Nipah virus infection in the hamster model. Scientific Reports, 2018, 8, 7604.	3.3	100
44	Experimental Infection of Syrian Hamsters With Aerosolized Nipah Virus. Journal of Infectious Diseases, 2018, 218, 1602-1610.	4.0	15
45	The quest for good explanations. PLoS Pathogens, 2018, 14, e1006818.	4.7	0
46	Breast milk and in utero transmission of HIV-1 select for envelope variants with unique molecular signatures. Retrovirology, 2017, 14, 6.	2.0	10
47	Taxonomy of the order Mononegavirales: update 2017. Archives of Virology, 2017, 162, 2493-2504.	2.1	173
48	Zoonotic Potential of Emerging Paramyxoviruses. Advances in Virus Research, 2017, 98, 1-55.	2.1	84
49	Inhibition of an Aquatic Rhabdovirus Demonstrates Promise of a Broad-Spectrum Antiviral for Use in Aquaculture. Journal of Virology, 2017, 91, .	3.4	29
50	Efficient and Robust <i>Paramyxoviridae</i> Reverse Genetics Systems. MSphere, 2017, 2, .	2.9	55
51	Analysis of Clinical HIV-1 Strains with Resistance to Maraviroc Reveals Strain-Specific Resistance Mutations, Variable Degrees of Resistance, and Minimal Cross-Resistance to Other CCR5 Antagonists. AIDS Research and Human Retroviruses, 2017, 33, 1220-1235.	1.1	8
52	Galectin-9 binds to O-glycans on protein disulfide isomerase. Glycobiology, 2017, 27, 878-887.	2.5	37
53	ldiosyncratic MòjiÄng virus attachment glycoprotein directs a host-cell entry pathway distinct from genetically related henipaviruses. Nature Communications, 2017, 8, 16060.	12.8	46
54	ICTV Virus Taxonomy Profile: Pneumoviridae. Journal of General Virology, 2017, 98, 2912-2913.	2.9	215

#	Article	IF	CITATIONS
55	The Microtubule Inhibitor Podofilox Inhibits an Early Entry Step of Human Cytomegalovirus. Viruses, 2016, 8, 295.	3.3	16
56	Constraints on the Genetic and Antigenic Variability of Measles Virus. Viruses, 2016, 8, 109.	3.3	39
57	Nipah Virus C Protein Recruits Tsg101 to Promote the Efficient Release of Virus in an ESCRT-Dependent Pathway. PLoS Pathogens, 2016, 12, e1005659.	4.7	31
58	Emerging Paramyxoviruses: Receptor Tropism and Zoonotic Potential. PLoS Pathogens, 2016, 12, e1005390.	4.7	39
59	ISG15 deficiency and increased viral resistance in humans but not mice. Nature Communications, 2016, 7, 11496.	12.8	156
60	Quantifying the Sensitivity of HIV-1 Viral Entry to Receptor and Coreceptor Expression. Journal of Physical Chemistry B, 2016, 120, 6189-6199.	2.6	5
61	Nipah virus matrix protein: expert hacker of cellular machines. FEBS Letters, 2016, 590, 2494-2511.	2.8	35
62	Sendai virus, an RNA virus with no risk of genomic integration, delivers CRISPR/Cas9 for efficient gene editing. Molecular Therapy - Methods and Clinical Development, 2016, 3, 16057.	4.1	40
63	Cross-reactive and cross-neutralizing activity of human mumps antibodies against a novel mumps virus from bats. Journal of Infectious Diseases, 2016, 215, jiw534.	4.0	7
64	Frequency and Env determinants of HIV-1 subtype C strains from antiretroviral therapy-naive subjects that display incomplete inhibition by maraviroc. Retrovirology, 2016, 13, 74.	2.0	4
65	Escape From Monoclonal Antibody Neutralization Affects Henipavirus Fitness In Vitro and In Vivo. Journal of Infectious Diseases, 2016, 213, 448-455.	4.0	14
66	Quantifying CD4/CCR5 Usage Efficiency of HIV-1 Env Using the Affinofile System. Methods in Molecular Biology, 2016, 1354, 3-20.	0.9	3
67	Optimized P2A for reporter gene insertion into Nipah virus results in efficient ribosomal skipping and wild-type lethality. Journal of General Virology, 2016, 97, 839-843.	2.9	10
68	The Matrix Protein of Nipah Virus Targets the E3-Ubiquitin Ligase TRIM6 to Inhibit the IKKε Kinase-Mediated Type-I IFN Antiviral Response. PLoS Pathogens, 2016, 12, e1005880.	4.7	81
69	Timing of Galectin-1 Exposure Differentially Modulates Nipah Virus Entry and Syncytium Formation in Endothelial Cells. Journal of Virology, 2015, 89, 2520-2529.	3.4	36
70	Mutational Analysis of Measles Virus Suggests Constraints on Antigenic Variation of the Glycoproteins. Cell Reports, 2015, 11, 1331-1338.	6.4	64
71	Galectin-1 Regulates Tissue Exit of Specific Dendritic Cell Populations. Journal of Biological Chemistry, 2015, 290, 22662-22677.	3.4	48
72	Efficient Reverse Genetics Reveals Genetic Determinants of Budding and Fusogenic Differences between Nipah and Hendra Viruses and Enables Real-Time Monitoring of Viral Spread in Small Animal Models of Henipavirus Infection. Journal of Virology, 2015, 89, 1242-1253.	3.4	62

#	Article	IF	CITATIONS
73	Broad-spectrum antivirals against viral fusion. Nature Reviews Microbiology, 2015, 13, 426-437.	28.6	189
74	Evidence for Ubiquitin-Regulated Nuclear and Subnuclear Trafficking among Paramyxovirinae Matrix Proteins. PLoS Pathogens, 2015, 11, e1004739.	4.7	60
75	Effects of singlet oxygen generated by a broad-spectrum viral fusion inhibitor on membrane nanoarchitecture. Nanomedicine: Nanotechnology, Biology, and Medicine, 2015, 11, 1163-1167.	3.3	15
76	Molecular recognition of human ephrinB2 cell surface receptor by an emergent African henipavirus. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, E2156-65.	7.1	47
77	Dose–response curve slope helps predict therapeutic potency and breadth of HIV broadly neutralizing antibodies. Nature Communications, 2015, 6, 8443.	12.8	44
78	Crystal Structure of the Pre-fusion Nipah Virus Fusion Glycoprotein Reveals a Novel Hexamer-of-Trimers Assembly. PLoS Pathogens, 2015, 11, e1005322.	4.7	59
79	Microbeââ,¬â€œHost Interactions are Positively and Negatively Regulated by Galectinââ,¬â€œGlycan Interactions. Frontiers in Immunology, 2014, 5, 284.	4.8	66
80	Evidence for henipavirus spillover into human populations in Africa. Nature Communications, 2014, 5, 5342.	12.8	143
81	Functional Rectification of the Newly Described African Henipavirus Fusion Glycoprotein (Gh-M74a). Journal of Virology, 2014, 88, 5171-5176.	3.4	14
82	Distinct HIV-1 entry phenotypes are associated with transmission, subtype specificity, and resistance to broadly neutralizing antibodies. Retrovirology, 2014, 11, 48.	2.0	21
83	Quantification of Entry Phenotypes of Macrophage-Tropic HIV-1 across a Wide Range of CD4 Densities. Journal of Virology, 2014, 88, 1858-1869.	3.4	92
84	The Rigid Amphipathic Fusion Inhibitor dUY11 Acts through Photosensitization of Viruses. Journal of Virology, 2014, 88, 1849-1853.	3.4	61
85	Singlet oxygen effects on lipid membranes: implications for the mechanism of action of broad-spectrum viral fusion inhibitors. Biochemical Journal, 2014, 459, 161-170.	3.7	42
86	CRISPR/Cas9 Allows Efficient and Complete Knock-In of a Destabilization Domain-Tagged Essential Protein in a Human Cell Line, Allowing Rapid Knockdown of Protein Function. PLoS ONE, 2014, 9, e95101.	2.5	38
87	Affinofile Assay for Identifying Macrophage-Tropic HIV-1. Bio-protocol, 2014, 4, .	0.4	8
88	A common mechanism of clinical HIV-1 resistance to the CCR5 antagonist maraviroc despite divergent resistance levels and lack of common gp120 resistance mutations. Retrovirology, 2013, 10, 43.	2.0	57
89	Comparison of Viral Env Proteins from Acute and Chronic Infections with Subtype C Human Immunodeficiency Virus Type 1 Identifies Differences in Glycosylation and CCR5 Utilization and Suggests a New Strategy for Immunogen Design. Journal of Virology, 2013, 87, 7218-7233.	3.4	119
90	Transmitted/Founder and Chronic HIV-1 Envelope Proteins Are Distinguished by Differential Utilization of CCR5. Journal of Virology, 2013, 87, 2401-2411.	3.4	66

#	Article	IF	CITATIONS
91	Affinofile profiling: How efficiency of CD4/CCR5 usage impacts the biological and pathogenic phenotype of HIV. Virology, 2013, 435, 81-91.	2.4	26
92	Interferon-Inducible Cholesterol-25-Hydroxylase Broadly Inhibits Viral Entry by Production of 25-Hydroxycholesterol. Immunity, 2013, 38, 92-105.	14.3	554
93	The magnitude of HIV-1 resistance to the CCR5 antagonist maraviroc may impart a differential alteration in HIV-1 tropism for macrophages and T-cell subsets. Virology, 2013, 442, 51-58.	2.4	20
94	The Greasy Response to Virus Infections. Cell Host and Microbe, 2013, 13, 375-377.	11.0	10
95	A Mechanistic Paradigm for Broad-Spectrum Antivirals that Target Virus-Cell Fusion. PLoS Pathogens, 2013, 9, e1003297.	4.7	88
96	Nipah Virus Envelope-Pseudotyped Lentiviruses Efficiently Target ephrinB2-Positive Stem Cell Populations In Vitro and Bypass the Liver Sink When Administered In Vivo. Journal of Virology, 2013, 87, 4794-4794.	3.4	1
97	HIV provides ample PAMPs for innate immune sensing. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 19183-19184.	7.1	6
98	Nipah Virus Envelope-Pseudotyped Lentiviruses Efficiently Target ephrinB2-Positive Stem Cell Populations <i>In Vitro</i> and Bypass the Liver Sink When Administered <i>In Vivo</i> . Journal of Virology, 2013, 87, 2094-2108.	3.4	27
99	Macrophage-tropic HIV-1 variants from brain demonstrate alterations in the way gp120 engages both CD4 and CCR5. Journal of Leukocyte Biology, 2013, 93, 113-126.	3.3	36
100	Individual N-Glycans Added at Intervals along the Stalk of the Nipah Virus G Protein Prevent Fusion but Do Not Block the Interaction with the Homologous F Protein. Journal of Virology, 2013, 87, 3119-3129.	3.4	18
101	Longitudinal Analysis of CCR5 and CXCR4 Usage in a Cohort of Antiretroviral Therapy-NaÃ <sup>-</sup> ve Subjects with Progressive HIV-1 Subtype C Infection. PLoS ONE, 2013, 8, e65950.	2.5	29
102	Cysteines in the Stalk of the Nipah Virus G Glycoprotein Are Located in a Distinct Subdomain Critical for Fusion Activation. Journal of Virology, 2012, 86, 6632-6642.	3.4	49
103	N-Glycans on the Nipah Virus Attachment Glycoprotein Modulate Fusion and Viral Entry as They Protect against Antibody Neutralization. Journal of Virology, 2012, 86, 11991-12002.	3.4	48
104	Henipavirus Receptor Usage and Tropism. Current Topics in Microbiology and Immunology, 2012, 359, 59-78.	1.1	50
105	Regulation of the nucleocytoplasmic trafficking of viral and cellular proteins by ubiquitin and small ubiquitinâ€related modifiers. Biology of the Cell, 2012, 104, 121-138.	2.0	24
106	The Soluble Serum Protein Gas6 Bridges Virion Envelope Phosphatidylserine to the TAM Receptor Tyrosine Kinase Axl to Mediate Viral Entry. Cell Host and Microbe, 2011, 9, 286-298.	11.0	165
107	Modes of paramyxovirus fusion: a Henipavirus perspective. Trends in Microbiology, 2011, 19, 389-399.	7.7	88
108	HIV-1 predisposed to acquiring resistance to maraviroc (MVC) and other CCR5 antagonists in vitro has an inherent, low-level ability to utilize MVC-bound CCR5 for entry. Retrovirology, 2011, 8, 89.	2.0	38

#	Article	IF	CITATIONS
109	Galectin-9 binding to cell surface protein disulfide isomerase regulates the redox environment to enhance T-cell migration and HIV entry. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 10650-10655.	7.1	220
110	Interactions of Human Complement with Virus Particles Containing the Nipah Virus Glycoproteins. Journal of Virology, 2011, 85, 5940-5948.	3.4	20
111	HIV-1 Escape from the CCR5 Antagonist Maraviroc Associated with an Altered and Less-Efficient Mechanism of gp120-CCR5 Engagement That Attenuates Macrophage Tropism. Journal of Virology, 2011, 85, 4330-4342.	3.4	70
112	Emerging paramyxoviruses: molecular mechanisms and antiviral strategies. Expert Reviews in Molecular Medicine, 2011, 13, e6.	3.9	41
113	Triggering of the Newcastle Disease Virus Fusion Protein by a Chimeric Attachment Protein That Binds to Nipah Virus Receptors. Journal of Biological Chemistry, 2011, 286, 17851-17860.	3.4	27
114	Containing the <i>Contagion</i> : Treating the Virus That Inspired the Film. Science Translational Medicine, 2011, 3, 105fs6.	12.4	3
115	Hendra and Nipah Infection: Pathology, Models and Potential Therapies. Infectious Disorders - Drug Targets, 2011, 11, 315-336.	0.8	30
116	A highly efficient short hairpin RNA potently down-regulates CCR5 expression in systemic lymphoid organs in the hu-BLT mouse model. Blood, 2010, 115, 1534-1544.	1.4	132
117	Constrained use of CCR5 on CD4+ lymphocytes by R5X4 HIV-1: Efficiency of Env–CCR5 interactions and low CCR5 expression determine a range of restricted CCR5-mediated entry. Virology, 2010, 402, 135-148.	2.4	11
118	An altered and more efficient mechanism of CCR5 engagement contributes to macrophage tropism of CCR5-using HIV-1 envelopes. Virology, 2010, 404, 269-278.	2.4	55
119	Positive Reinforcement for Viruses. Chemistry and Biology, 2010, 17, 1049-1051.	6.0	11
120	Combined chloroquine and ribavirin treatment does not prevent death in a hamster model of Nipah and Hendra virus infection. Journal of General Virology, 2010, 91, 765-772.	2.9	104
121	A Quantitative and Kinetic Fusion Protein-Triggering Assay Can Discern Distinct Steps in the Nipah Virus Membrane Fusion Cascade. Journal of Virology, 2010, 84, 8033-8041.	3.4	42
122	HIV-1 Resistance to CCR5 Antagonists Associated with Highly Efficient Use of CCR5 and Altered Tropism on Primary CD4 <sup>+</sup> T Cells. Journal of Virology, 2010, 84, 6505-6514.	3.4	59
123	Endothelial Galectin-1 Binds to Specific Glycans on Nipah Virus Fusion Protein and Inhibits Maturation, Mobility, and Function to Block Syncytia Formation. PLoS Pathogens, 2010, 6, e1000993.	4.7	62
124	Ubiquitin-Regulated Nuclear-Cytoplasmic Trafficking of the Nipah Virus Matrix Protein Is Important for Viral Budding. PLoS Pathogens, 2010, 6, e1001186.	4.7	110
125	Redirecting Lentiviral Vectors Pseudotyped with Sindbis Virus-Derived Envelope Proteins to DC-SIGN by Modification of N-Linked Clycans of Envelope Proteins. Journal of Virology, 2010, 84, 6923-6934.	3.4	46
126	A broad-spectrum antiviral targeting entry of enveloped viruses. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 3157-3162.	7.1	214

#	Article	IF	CITATIONS
127	A Novel Receptor-induced Activation Site in the Nipah Virus Attachment Glycoprotein (G) Involved in Triggering the Fusion Glycoprotein (F). Journal of Biological Chemistry, 2009, 284, 1628-1635.	3.4	83
128	Galectin-1 Co-clusters CD43/CD45 on Dendritic Cells and Induces Cell Activation and Migration through Syk and Protein Kinase C Signaling. Journal of Biological Chemistry, 2009, 284, 26860-26870.	3.4	78
129	Human milk oligosaccharides reduce HIV-1-gp120 binding to dendritic cell-specific ICAM3-grabbing non-integrin (DC-SIGN). British Journal of Nutrition, 2009, 101, 482-486.	2.3	109
130	Targeted Transduction via CD4 by a Lentiviral Vector Uses a Clathrin-Mediated Entry Pathway. Journal of Virology, 2009, 83, 13026-13031.	3.4	18
131	Elite Suppressor–Derived HIV-1 Envelope Glycoproteins Exhibit Reduced Entry Efficiency and Kinetics. PLoS Pathogens, 2009, 5, e1000377.	4.7	93
132	A Quantitative Affinity-Profiling System That Reveals Distinct CD4/CCR5 Usage Patterns among Human Immunodeficiency Virus Type 1 and Simian Immunodeficiency Virus Strains. Journal of Virology, 2009, 83, 11016-11026.	3.4	84
133	Adaptive Mutations in a Human Immunodeficiency Virus Type 1 Envelope Protein with a Truncated V3 Loop Restore Function by Improving Interactions with CD4. Journal of Virology, 2009, 83, 11005-11015.	3.4	30
134	Development of a neutralization assay for Nipah virus using pseudotype particles. Journal of Virological Methods, 2009, 160, 1-6.	2.1	75
135	Inefficient entry of vicriviroc-resistant HIV-1 via the inhibitor-CCR5 complex at low cell surface CCR5 densities. Virology, 2009, 387, 296-302.	2.4	39
136	A catalytically and genetically optimized β-lactamase-matrix based assay for sensitive, specific, and higher throughput analysis of native henipavirus entry characteristics. Virology Journal, 2009, 6, 119.	3.4	29
137	MicroRNA profiling identifies miR-34a and miR-21 and their target genes JAG1 and WNT1 in the coordinate regulation of dendritic cell differentiation. Blood, 2009, 114, 404-414.	1.4	256
138	Evil versus 'eph-ective' use of ephrin-B2. Nature Structural and Molecular Biology, 2008, 15, 540-542.	8.2	11
139	HIVâ€1 ssRNA triggers a vitamin Dâ€dependent antiâ€viral pathway in human monocytes. FASEB Journal, 2008, 22, 672.22.	0.5	0
140	Pathobiology of henipavirus entry: insights into therapeutic strategies. Future Virology, 2007, 2, 267-282.	1.8	3
141	Polybasic KKR Motif in the Cytoplasmic Tail of Nipah Virus Fusion Protein Modulates Membrane Fusion by Inside-Out Signaling. Journal of Virology, 2007, 81, 4520-4532.	3.4	91
142	Identification of the Optimal DC-SIGN Binding Site on Human Immunodeficiency Virus Type 1 gp120. Journal of Virology, 2007, 81, 8325-8336.	3.4	39
143	Single Amino Acid Changes in the Nipah and Hendra Virus Attachment Glycoproteins Distinguish EphrinB2 from EphrinB3 Usage. Journal of Virology, 2007, 81, 10804-10814.	3.4	91
144	Efficient Construction of an Inverted Minimal H1 Promoter Driven siRNA Expression Cassette: Facilitation of Promoter and siRNA Sequence Exchange. PLoS ONE, 2007, 2, e767.	2.5	1

#	Article	IF	CITATIONS
145	Envelope-Receptor Interactions in Nipah Virus Pathobiology. Annals of the New York Academy of Sciences, 2007, 1102, 51-65.	3.8	36
146	Anthrax oedema toxin induces anthrax toxin receptor expression in monocyte-derived cells. Molecular Microbiology, 2006, 61, 324-337.	2.5	43
147	Rho GTPase activity modulates paramyxovirus fusion protein-mediated cell–cell fusion. Virology, 2006, 350, 323-334.	2.4	33
148	Two Key Residues in EphrinB3 Are Critical for Its Use as an Alternative Receptor for Nipah Virus. PLoS Pathogens, 2006, 2, e7.	4.7	245
149	N-Glycans on Nipah Virus Fusion Protein Protect against Neutralization but Reduce Membrane Fusion and Viral Entry. Journal of Virology, 2006, 80, 4878-4889.	3.4	168
150	Galectin-1-Matured Human Monocyte-Derived Dendritic Cells Have Enhanced Migration through Extracellular Matrix. Journal of Immunology, 2006, 177, 216-226.	0.8	112
151	Lentiviral vector retargeting to P-glycoprotein on metastatic melanoma through intravenous injection. Nature Medicine, 2005, 11, 346-352.	30.7	202
152	EphrinB2 is the entry receptor for Nipah virus, an emergent deadly paramyxovirus. Nature, 2005, 436, 401-405.	27.8	434
153	Novel Innate Immune Functions for Galectin-1: Galectin-1 Inhibits Cell Fusion by Nipah Virus Envelope Glycoproteins and Augments Dendritic Cell Secretion of Proinflammatory Cytokines. Journal of Immunology, 2005, 175, 413-420.	0.8	156
154	Binding and Transfer of Human Immunodeficiency Virus by DC-SIGN+ Cells in Human Rectal Mucosa. Journal of Virology, 2005, 79, 5762-5773.	3.4	108
155	DC-SIGN Binds to HIV-1 Glycoprotein 120 in a Distinct but Overlapping Fashion Compared with ICAM-2 and ICAM-3. Journal of Biological Chemistry, 2004, 279, 19122-19132.	3.4	57
156	Specific Interaction of Feline Immunodeficiency Virus Surface Glycoprotein with Human DC-SIGN. Journal of Virology, 2004, 78, 2597-2600.	3.4	30
157	Sugar and Spice: Viral Envelope-DC-SIGN Interactions in HIV Pathogenesis. Current HIV Research, 2003, 1, 87-99.	0.5	25
158	Human Immunodeficiency Virus Envelope (gp120) Binding to DC-SIGN and Primary Dendritic Cells Is Carbohydrate Dependent but Does Not Involve 2G12 or Cyanovirin Binding Sites: Implications for Structural Analyses of gp120-DC-SIGN Binding. Journal of Virology, 2002, 76, 12855-12865.	3.4	90
159	Expression of human immunodeficiency virus (HIV)–binding lectin DC-SIGNR: Consequences for HIV infection and immunity. Human Pathology, 2002, 33, 652-659.	2.0	35
160	Constitutive and induced expression of DC-SIGN on dendritic cell and macrophage subpopulations in situ and in vitro. Journal of Leukocyte Biology, 2002, 71, 445-57.	3.3	311
161	Placental expression of DC-SIGN may mediate intrauterine vertical transmission of HIV. Journal of Pathology, 2001, 195, 586-592.	4.5	135
162	CCR5 and CXCR4 expression correlated with X4 and R5 HIV-1 infection yet not sustained replication in Th1 and Th2 cells. Aids, 2001, 15, 1941-1949.	2.2	31

#	Article	IF	CITATIONS
163	DC-SIGNR, a DC-SIGN homologue expressed in endothelial cells, binds to human and simian immunodeficiency viruses and activates infection in trans. Proceedings of the National Academy of Sciences of the United States of America, 2001, 98, 2670-2675.	7.1	296
164	CD4-Independent Use of Rhesus CCR5 by Human Immunodeficiency Virus Type 2 Implicates an Electrostatic Interaction between the CCR5 N Terminus and the gp120 C4 Domain. Journal of Virology, 2001, 75, 10766-10778.	3.4	22
165	cis Expression of DC-SIGN Allows for More Efficient Entry of Human and Simian Immunodeficiency Viruses via CD4 and a Coreceptor. Journal of Virology, 2001, 75, 12028-12038.	3.4	170
166	Palmitoylation of CCR5 Is Critical for Receptor Trafficking and Efficient Activation of Intracellular Signaling Pathways. Journal of Biological Chemistry, 2001, 276, 23795-23804.	3.4	125
167	DC-SIGN Interactions with Human Immunodeficiency Virus Type 1 and 2 and Simian Immunodeficiency Virus. Journal of Virology, 2001, 75, 4664-4672.	3.4	210
168	IL-13 and TNF-α inhibit dual-tropic HIV-1 in primary macrophages by reduction of surface expression of CD4, chemokine receptors CCR5, CXCR4 and post-entry viral gene expression. European Journal of Immunology, 2000, 30, 1340-1349.	2.9	50
169	Expression and Coreceptor Function of APJ for Primate Immunodeficiency Viruses. Virology, 2000, 276, 435-444.	2.4	39
170	The Role of HIV-Related Chemokine Receptors and Chemokines in Human Erythropoiesis in Vitro. Stem Cells, 2000, 18, 128-138.	3.2	32
171	Expression and coreceptor activity of STRL33/Bonzo on primary peripheral blood lymphocytes. Blood, 2000, 96, 41-49.	1.4	79
172	Multiple nonfunctional alleles of CCR5 are frequent in various human populations. Blood, 2000, 96, 1638-1645.	1.4	103
173	Simian Immunodeficiency Virus Utilizes Human and Sooty Mangabey but Not Rhesus Macaque STRL33 for Efficient Entry. Journal of Virology, 2000, 74, 5075-5082.	3.4	41
174	Expression and coreceptor activity of STRL33/Bonzo on primary peripheral blood lymphocytes. Blood, 2000, 96, 41-49.	1.4	33
175	Multiple nonfunctional alleles of CCR5 are frequent in various human populations. Blood, 2000, 96, 1638-1645.	1.4	32
176	Simian Immunodeficiency Virus Utilizes Human and Sooty Mangabey but Not Rhesus Macaque STRL33 for Efficient Entry. Journal of Virology, 2000, 74, 5075-5082.	3.4	3
177	Microglia Express CCR5, CXCR4, and CCR3, but of These, CCR5 Is the Principal Coreceptor for Human Immunodeficiency Virus Type 1 Dementia Isolates. Journal of Virology, 1999, 73, 205-213.	3.4	293
178	Interferon-Î <sup>3</sup> Upregulates CCR5 Expression in Cord and Adult Blood Mononuclear Phagocytes. Blood, 1999, 93, 1137-1144.	1.4	75
179	Coreceptor/Chemokine Receptor Expression on Human Hematopoietic Cells: Biological Implications for Human Immunodeficiency Virus–Type 1 Infection. Blood, 1999, 93, 1145-1156.	1.4	83
180	CCR5 Binds Multiple CC-Chemokines: MCP-3 Acts as a Natural Antagonist. Blood, 1999, 94, 1899-1905.	1.4	234

#	Article	IF	CITATIONS
181	Quantification of CD4, CCR5, and CXCR4 levels on lymphocyte subsets, dendritic cells, and differentially conditioned monocyte-derived macrophages. Proceedings of the National Academy of Sciences of the United States of America, 1999, 96, 5215-5220.	7.1	528
182	Epitope Mapping of CCR5 Reveals Multiple Conformational States and Distinct but Overlapping Structures Involved in Chemokine and Coreceptor Function. Journal of Biological Chemistry, 1999, 274, 9617-9626.	3.4	327
183	Extracellular Cysteines of CCR5 Are Required for Chemokine Binding, but Dispensable for HIV-1 Coreceptor Activity. Journal of Biological Chemistry, 1999, 274, 18902-18908.	3.4	104
184	CCR5 HIV-1 Coreceptor Activity. Journal of Biological Chemistry, 1999, 274, 28413-28419.	3.4	18
185	Differences in phosphorylation of the IL-2R associated JAK/STAT proteins between HTLV-I (+), IL-2-independent and IL-2-dependent cell lines and uncultured leukemic cells from patients with adult T-cell lymphoma/leukemia. Leukemia Research, 1999, 23, 373-384.	0.8	31
186	A novel chemotherapeutic regimen (interferon alfa, zidovudine, and etretinate) for adult T-cell lymphoma resulting in rapid tumor destruction. Journal of the American Academy of Dermatology, 1999, 40, 116-121.	1.2	14
187	Bone marrow CD34+ cells and megakaryoblasts secrete β-chemokines that block infection of hematopoietic cells by M-tropic R5 HIV. Journal of Clinical Investigation, 1999, 104, 1739-1749.	8.2	51
188	Interferon-Î <sup>3</sup> Upregulates CCR5 Expression in Cord and Adult Blood Mononuclear Phagocytes. Blood, 1999, 93, 1137-1144.	1.4	15
189	Coreceptor/Chemokine Receptor Expression on Human Hematopoietic Cells: Biological Implications for Human Immunodeficiency Virus–Type 1 Infection. Blood, 1999, 93, 1145-1156.	1.4	35
190	CCR5 Binds Multiple CC-Chemokines: MCP-3 Acts as a Natural Antagonist. Blood, 1999, 94, 1899-1905.	1.4	66
191	Use of GPR1, GPR15, and STRL33 as Coreceptors by Diverse Human Immunodeficiency Virus Type 1 and Simian Immunodeficiency Virus Envelope Proteins. Virology, 1998, 249, 367-378.	2.4	135
192	An Intricate Web: Chemokine Receptors, HIVâ $\in$ l and Hematopoiesis. Stem Cells, 1998, 16, 79-88.	3.2	68
193	Genetic Acceleration of AIDS Progression by a Promoter Variant of CCR5. , 1998, 282, 1907-1911.		412
194	An Orphan Seven-Transmembrane Domain Receptor Expressed Widely in the Brain Functions as a Coreceptor for Human Immunodeficiency Virus Type 1 and Simian Immunodeficiency Virus. Journal of Virology, 1998, 72, 7934-7940.	3.4	183
195	Influence of the <i>CCR2-V64I</i> Polymorphism on Human Immunodeficiency Virus Type 1 Coreceptor Activity and on Chemokine Receptor Function of CCR2b, CCR3, CCR5, and CXCR4. Journal of Virology, 1998, 72, 7450-7458.	3.4	138
196	CD4-independent, CCR5-dependent infection of brain capillary endothelial cells by a neurovirulent simian immunodeficiency virus strain. Proceedings of the National Academy of Sciences of the United States of America, 1997, 94, 14742-14747.	7.1	251
197	Utilization of chemokine receptors, orphan receptors, and herpesvirus-encoded receptors by diverse human and simian immunodeficiency viruses. Journal of Virology, 1997, 71, 8999-9007.	3.4	321
198	Association of RNase mitochondrial RNA processing enzyme with ribonuclease P in higher ordered structures in the nucleolus: a possible coordinate role in ribosome biogenesis Proceedings of the National Academy of Sciences of the United States of America, 1996, 93, 11471-11476.	7.1	71

2

#	Article	IF	CITATIONS
199	Molecular Structure and Function of Autoantigens in Systemic Sclerosis. International Reviews of Immunology, 1995, 12, 129-144.	3.3	16

200 Quantification of HIV/SIV Coreceptor Expression. , 0, , 53-66.